ALPS Medical Breakthroughs ETF
Price through Oct 2 · Flows through unavailable. Figures use the latest available records, not a live quote. Fund details retrieved Oct 2. Holdings snapshot retrieved Oct 2.
The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
SOURCE: MARKET TAPE & DAILY CREATION/REDEMPTION RECORDS · 6M SHOWN
Recent fund-flow records are unavailable, while the price has returned +9.6% so far this year. At 0.50% a year it is not the cheapest way in — FDHT has a reported fee of 0.39%.
COMPOSED FROM THE FUND’S OWN DAILY RECORDS · UPDATED WITH EACH REFRESH
| 1 week | -2.4% |
| 1 month | -17.3% |
| 3 months | -13.5% |
| 6 months | +7.3% |
| YTD | +9.6% |
| 1 year | +43.9% |
| 3 years | — |
PRICE RETURN, DISTRIBUTIONS NOT REINVESTED
| 1 week | — |
| 1 month | — |
| 3 months | — |
| YTD | — |
| 1 year | — |
CREATION/REDEMPTION DOLLARS, DAILY RECORDS
VOLATILITY & DRAWDOWN FROM THE DAILY TAPE · CONCENTRATION FROM THE LATEST DISCLOSED BOOK
Due diligence cuts both ways. These funds sit on the same shelf and beat SBIO on at least one dimension that matters — the fee, the asset base, or where the money is going.
| Fund | Fee | Assets | Flow, 1M | The case | |
|---|---|---|---|---|---|
| SPDW State Street SPDR Portfolio Developed World ex-US ETF | 0.03% | $41.5B | +$286M | -47bp on fee · 363× the assets · +$286M in over the month | Head-to-head |
| SPMD State Street SPDR Portfolio S&P 400 Mid Cap ETF | 0.03% | $18.2B | +$199M | -47bp on fee · 159× the assets · +$199M in over the month | Head-to-head |
| IDEV iShares Core MSCI International Developed Markets ETF | 0.04% | $32.9B | +$497M | -46bp on fee · 288× the assets · +$497M in over the month | Head-to-head |
| IGSB iShares 1-5 Year Investment Grade Corporate Bond ETF | 0.04% | $23.7B | +$575M | -46bp on fee · 207× the assets · +$575M in over the month | Head-to-head |
| IGIB iShares 5-10 Year Investment Grade Corporate Bond ETF | 0.04% | $18.6B | +$412M | -46bp on fee · 163× the assets · +$412M in over the month | Head-to-head |